162 related articles for article (PubMed ID: 38407042)
21. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
[TBL] [Abstract][Full Text] [Related]
22. Insights into CD47/SIRPα axis-targeting tumor immunotherapy.
Zhang X; Fan J; Ju D
Antib Ther; 2018 Sep; 1(2):37-42. PubMed ID: 34056543
[TBL] [Abstract][Full Text] [Related]
23. "Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein α (SIRPα) antagonists that enhance antibody-dependent cellular phagocytosis.
Ho CC; Guo N; Sockolosky JT; Ring AM; Weiskopf K; Özkan E; Mori Y; Weissman IL; Garcia KC
J Biol Chem; 2015 May; 290(20):12650-63. PubMed ID: 25837251
[TBL] [Abstract][Full Text] [Related]
24. The CD47-SIRPα axis is a promising target for cancer immunotherapies.
Hao Y; Zhou X; Li Y; Li B; Cheng L
Int Immunopharmacol; 2023 Jul; 120():110255. PubMed ID: 37187126
[TBL] [Abstract][Full Text] [Related]
25. The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a.
Peluso MO; Adam A; Armet CM; Zhang L; O'Connor RW; Lee BH; Lake AC; Normant E; Chappel SC; Hill JA; Palombella VJ; Holland PM; Paterson AM
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32345627
[TBL] [Abstract][Full Text] [Related]
26. Expression of CD47 and SIRPα Macrophage Immune-Checkpoint Pathway in Non-Small-Cell Lung Cancer.
Giatromanolaki A; Mitrakas A; Anestopoulos I; Kontosis A; Koukourakis IM; Pappa A; Panayiotidis MI; Koukourakis MI
Cancers (Basel); 2022 Apr; 14(7):. PubMed ID: 35406573
[TBL] [Abstract][Full Text] [Related]
27. RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages.
Cabrales P
Transl Oncol; 2019 Apr; 12(4):626-632. PubMed ID: 30738349
[TBL] [Abstract][Full Text] [Related]
28. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
[TBL] [Abstract][Full Text] [Related]
29. SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.
Ponce LP; Fenn NC; Moritz N; Krupka C; Kozik JH; Lauber K; Subklewe M; Hopfner KP
Oncotarget; 2017 Feb; 8(7):11284-11301. PubMed ID: 28061465
[TBL] [Abstract][Full Text] [Related]
30. Design of a novel chimeric peptide via dual blockade of CD47/SIRPα and PD-1/PD-L1 for cancer immunotherapy.
Hu Z; Li W; Chen S; Chen D; Xu R; Zheng D; Yang X; Li S; Zhou X; Niu X; Xiao Y; He Z; Li H; Liu J; Sui X; Gao Y
Sci China Life Sci; 2023 Oct; 66(10):2310-2328. PubMed ID: 37115491
[TBL] [Abstract][Full Text] [Related]
31. Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed.
Qu T; Li B; Wang Y
Biomark Res; 2022 Apr; 10(1):20. PubMed ID: 35418166
[TBL] [Abstract][Full Text] [Related]
32. ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile.
Kauder SE; Kuo TC; Harrabi O; Chen A; Sangalang E; Doyle L; Rocha SS; Bollini S; Han B; Sim J; Pons J; Wan HI
PLoS One; 2018; 13(8):e0201832. PubMed ID: 30133535
[TBL] [Abstract][Full Text] [Related]
33. Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy.
Chen H; Yang Y; Deng Y; Wei F; Zhao Q; Liu Y; Liu Z; Yu B; Huang Z
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110357
[TBL] [Abstract][Full Text] [Related]
34. The Ap-2α/Elk-1 axis regulates Sirpα-dependent tumor phagocytosis by tumor-associated macrophages in colorectal cancer.
Wang X; Luo X; Chen C; Tang Y; Li L; Mo B; Liang H; Yu S
Signal Transduct Target Ther; 2020 Apr; 5(1):35. PubMed ID: 32296015
[TBL] [Abstract][Full Text] [Related]
35. BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells.
van Helden MJ; Zwarthoff SA; Arends RJ; Reinieren-Beeren IMJ; Paradé MCBC; Driessen-Engels L; de Laat-Arts K; Damming D; Santegoeds-Lenssen EWH; van Kuppeveld DWJ; Lodewijks I; Olsman H; Matlung HL; Franke K; Mattaar-Hepp E; Stokman MEM; de Wit B; Glaudemans DHRF; van Wijk DEJW; Joosten-Stoffels L; Schouten J; Boersema PJ; van der Vleuten M; Sanderink JWH; Kappers WA; van den Dobbelsteen D; Timmers M; Ubink R; Rouwendal GJA; Verheijden G; van der Lee MMC; Dokter WHA; van den Berg TK
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37068796
[TBL] [Abstract][Full Text] [Related]
36. Versatile activatable vSIRPα-probe for cancer-targeted imaging and macrophage-mediated phagocytosis of cancer cells.
Ko YJ; Lee JW; Kim H; Cho E; Yang Y; Kim IS; Kim SH; Kwon IC
J Control Release; 2020 Jul; 323():376-386. PubMed ID: 32335154
[TBL] [Abstract][Full Text] [Related]
37. CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity.
de Silva S; Fromm G; Shuptrine CW; Johannes K; Patel A; Yoo KJ; Huang K; Schreiber TH
Cancer Immunol Res; 2020 Feb; 8(2):230-245. PubMed ID: 31852716
[TBL] [Abstract][Full Text] [Related]
38. Recent Advances of Tumor Therapy Based on the CD47-SIRPα Axis.
Wang Y; Zhao C; Liu Y; Wang C; Jiang H; Hu Y; Wu J
Mol Pharm; 2022 May; 19(5):1273-1293. PubMed ID: 35436123
[TBL] [Abstract][Full Text] [Related]
39. Extracellular Vesicles-Derived Hybrid Nanoplatforms for Amplified CD47 Blockade-Based Cancer Immunotherapy.
Tang L; Yin Y; Cao Y; Fu C; Liu H; Feng J; Wang W; Liang XJ
Adv Mater; 2023 Sep; 35(35):e2303835. PubMed ID: 37384818
[TBL] [Abstract][Full Text] [Related]
40. Signal regulatory protein alpha blockade potentiates tumoricidal effects of macrophages on gastroenterological neoplastic cells in syngeneic immunocompetent mice.
Abe T; Tanaka Y; Piao J; Tanimine N; Oue N; Hinoi T; Garcia NV; Miyasaka M; Matozaki T; Yasui W; Ohdan H
Ann Gastroenterol Surg; 2018 Nov; 2(6):451-462. PubMed ID: 30460349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
